Using lisinopril to reduce harmful effects from acute radiation exposure
Official title: MITIGATION OF MULTI-ORGAN DELAYED EFFECTS OF ACUTE RADIATION EXPOSURE (DEARE) WITH ACE-INHIBITOR LISINOPRIL
Funded at Medical College of Wisconsin · NIH-11101189 · Data updated 2026-11-12
This study is looking at whether lisinopril, a medicine for high blood pressure, can help reduce lung damage caused by radiation exposure in people who have experienced acute radiation syndrome.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Medical College of Wisconsin NIH-funded |
| Lab location | 1 site (Milwaukee, United States) |
| Project start | July 1, 2023 |
| Project end | June 30, 2025 |
| Funding year | 2024 |
| Award (this year) | $998,346 |
| NIH project number | 75N93023C00013-P00005-9999-1 |
| Project ID | NIH-11101189 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals who have experienced acute radiation exposure and are at risk for developing delayed multi-organ toxicities.
✕Less likely to help
Patients who have not been exposed to acute radiation or those with pre-existing conditions that contraindicate the use of lisinopril may not benefit from this research.
What this research studies
This research investigates the potential of lisinopril, a medication commonly used for high blood pressure, to mitigate the delayed effects of acute radiation exposure, known as DEARE. The study aims to optimize the dosage of lisinopril to effectively reduce radiation-induced lung damage and assess its efficacy in patients who have suffered from hematologic acute radiation syndrome. By leveraging previous animal studies and the established safety profile of lisinopril in humans, the research seeks to advance this treatment through the necessary regulatory processes for FDA approval.
Why it matters
Potential benefit: If successful, this research could provide a new FDA-approved treatment option to protect patients from the long-term effects of acute radiation exposure.
How similar studies have gone: While there have been studies on the effects of lisinopril in other contexts, this specific application for mitigating DEARE is novel and has not been extensively tested.
Where this research is happening
-
Medical College of Wisconsin
Milwaukee, United States Active
Researchers
- Principal investigator: Landrum, Jill — Medical College of Wisconsin
- Study coordinator: Landrum, Jill
Related research
Other NIH-funded projects on the same topics.
-
Gas Marble therapy to protect skin after radiation exposure
This grant tests a new gas-based treatment delivered as gas marbles to help skin recover after radiation damage.
-
A drug that helps repair DNA after radiation exposure
A new drug candidate aims to help the body repair damaged DNA after accidental or wartime radiation exposure to reduce organ injury and death.
-
Non-invasive skin biomarkers for radiation exposure
A study to find and measure skin biomarkers that indicate radiation exposure using a painless tape-stripping method on skin.
-
Restoring bone marrow blood vessels to prevent delayed radiation damage
This project aims to help people exposed to acute radiation by repairing the bone marrow’s blood vessel network to support healthier blood cell recovery over time.
-
Raman-based quick triage for radiation exposure
A new approach uses Raman spectroscopy and AI to quickly estimate radiation dose in people exposed to a radiological event, helping doctors decide who needs urgent treatment.
-
ACE2-agonist to reduce long-term radiation damage after ARS
Aims to test an ACE2-activating drug (diminazene aceturate) to lessen long-term organ damage after acute radiation exposure in adults.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.